ProMIS Neurosciences Reports Positive Interim PMN310 Trial Data

What happened

ProMIS Neurosciences reported interim safety and biomarker data from its Phase 1b PRECISE-AD trial evaluating PMN310, an investigational antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease. The company exceeded enrollment targets with 144 patients enrolled (target was 128), with 136 included in the safety analysis. Patients received monthly intravenous infusions at doses of 350 mg, 700 mg, or 1,400 mg, or placebo, using 3-to-1 randomization. The study population had a mean age of approximately 73 years, with 58% women, and included 11% APOE4 homozygotes and 50% APOE4 heterozygotes. The blinded interim analysis showed no cases of ARIA-E (amyloid-related imaging abnormalities with edema), no treatment-related serious adverse events, and no treatment-related discontinuations. The total ARIA rate was 4.4%, consisting entirely of mild, asymptomatic ARIA-H cases (microhemorrhages). Biomarker data indicated positive target engagement, with 68.5% of patients showing declines in plasma pTau217 and 62.5% showing decreases in CSF MTBR-tau243.

Why it matters

The interim results address a critical safety concern for Alzheimer's therapies targeting amyloid-beta. Approved anti-amyloid treatments have faced challenges with ARIA, particularly brain swelling that can require treatment modifications or discontinuation. PMN310's design aims to selectively target toxic oligomers while avoiding amyloid plaques and vascular deposits, theoretically reducing ARIA risk. The absence of ARIA-E cases across all dose levels and genotypes, including high-risk APOE4 carriers, supports this differentiation strategy. The observed 4.4% ARIA-H rate appeared consistent with rates in untreated placebo populations rather than elevated rates seen with some competing therapies. Positive biomarker responses suggest the antibody is engaging its intended target. PMN310 received Fast Track designation from the FDA in July 2025, potentially accelerating its development pathway if efficacy is demonstrated.

Bigger picture

The Alzheimer's treatment landscape has shifted following approvals of anti-amyloid antibodies, but safety profiles remain a competitive differentiator. ARIA complications have led to treatment restrictions, monitoring requirements, and exclusion of certain patient populations from approved therapies. ProMIS's selective targeting approach represents an alternative mechanism within the anti-amyloid class. The blinded interim data provides no clinical efficacy information yet, which remains the ultimate determinant of commercial viability. However, a favorable safety profile combined with demonstrated target engagement could position PMN310 as a potentially safer alternative if efficacy is established. The company's ability to exceed enrollment targets suggests continued clinical trial execution capability heading into the final study phases.

What to watch

The 12-month topline results expected in early 2027 will be the critical milestone, as they will include unblinded clinical outcome measures evaluating whether PMN310 slows cognitive decline. Investors should monitor whether the ARIA safety profile holds across the full treatment period and higher cumulative doses. Watch for any updates on regulatory interactions following these interim results, given the Fast Track designation. Long-term, the company will need to demonstrate differentiated efficacy or safety versus approved Alzheimer's therapies to establish a competitive position. The company is hosting a webinar to discuss these results, which may provide additional context on biomarker interpretations and next steps.